BL-B01D1, an EGFR–HER3 Bispecific ADC, Shows Promising Activity in Advanced Urothelial Carcinoma: Phase II Results
In a phase II single-arm study, BL-B01D1 demonstrated a 44.1% confirmed ORR and median PFS of 7.3 months at 2.2 mg/kg in patients with advanced urothelial carcinoma after prior systemic therapy, with predictable hematologic toxicity.